Live Breaking News & Updates on Legato Capital Management|Page 13

Stay updated with breaking news from Legato capital management. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Lisanti Capital Growth LLC Purchases Shares of 59,165 Oddity Tech Ltd. (NASDAQ:ODD)

Lisanti Capital Growth LLC purchased a new stake in shares of Oddity Tech Ltd. (NASDAQ:ODD – Free Report) in the fourth quarter, HoldingsChannel.com reports. The firm purchased 59,165 shares of the company’s stock, valued at approximately $2,753,000. A number of other large investors also recently modified their holdings of ODD. M&T Bank Corp purchased a […] ....

New York , United States , Oddity Tech Ltd , Td Asset Management Inc , Legato Capital Management , York State Common Retirement Fund , Lisanti Capital Growth , Morgan Stanley , Mt Bank Corp , Oddity Tech , Free Report , Management Inc , Capital Management , New York State Common Retirement Fund , Tech Stock Down , Get Free Report , Visit Holdingschannel , Oddity Tech Daily , Nasdaq Odd , Computer And Technology , Sec Filings , Hedge Fund Holdings , Institutional Investor Holdings ,

Zeta Global (NASDAQ:ZETA) Given New $18.00 Price Target at Oppenheimer

Zeta Global (NASDAQ:ZETA) Given New $18.00 Price Target at Oppenheimer
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United States , William Blair , First Eagle Investment Management , Legato Capital Management , Blue Trust Inc , Zeta Global Holdings Corp , Vanguard Group Inc , Insight Wealth Strategies , Needham Company , Zeta Global , Get Free Report , Wealth Strategies , Capital Management , Eagle Investment Management , Global Holdings , Zeta Marketing Platform , Consumer Data , Zeta Global Daily ,

Oppenheimer Reiterates "Market Perform" Rating for ACADIA Pharmaceuticals (NASDAQ:ACAD)

Oppenheimer reiterated their market perform rating on shares of ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) in a report published on Monday morning, Benzinga reports. They currently have a $19.00 target price on the biopharmaceutical company’s stock. ACAD has been the topic of a number of other research reports. JPMorgan Chase & Co. decreased their price […] ....

United States , Robertw Baird , Brendan Teehan , Stephen Davis , Quest Partners , Pharmaceuticals Daily , Pharmaceuticals Trading Down , Royal Bank , Securities Exchange Commission , Legato Capital Management , China Universal Asset Management Co , Pharmaceuticals Inc , Jpmorgan Chase Co , Acadian Asset Management , Pharmaceuticals Company Profile , Free Report , Moderate Buy , Trading Down , Get Free Report , Exchange Commission , Universal Asset Management , Management Fondsmaeglerselskab , Asset Management , Acadia Pharmaceuticals , Nasdaq Acad , Reiterated Rating ,

Immunocore Holdings plc (NASDAQ:IMCR) Given Average Recommendation of "Moderate Buy" by Brokerages

Immunocore Holdings plc (NASDAQ:IMCR – Get Free Report) has earned a consensus rating of “Moderate Buy” from the fifteen ratings firms that are currently covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. The average twelve-month target price among […] ....

Recursos Ltda , Immunocore Holdings , Canaccord Genuity Group , Immunocore Company Profile , Legato Capital Management , China Universal Asset Management Co , Investment Management , Exchange Traded Concepts , Needham Company , Get Free Report , Genuity Group , Universal Asset Management , Traded Concepts , Gestao De Recursos , Capital Management , Get Free , Immunocore Daily , Nasdaq Imcr ,